SMC ‘U-turn’ offers lifeline to Scottish skin cancer patients
Opdivo (nivolumab) now recommended to treat Scottish NHS patients with advanced skin cancer.
The Scottish Medicines Consortium (SMC) has now recommended Bristol-Myers Squibb's (BMS) Opdivo (nivolumab) to treat Scottish NHS patients with advanced skin cancer. The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access in Scotland on par with the rest of the UK. This potentially life-extending treatment option will be made available for previously-untreated adult patients with advanced (unresectable or metastatic) melanoma. The incidence of melanoma in Scotland has risen by 30% over the last 10 years – a rate higher than any other common cancer, including the country’s biggest cancer killer, lung cancer.
“Today’s decision will be welcomed by clinicians in Scotland; it means that we can now offer our patients this exciting new medicine. Our understanding of the science of tumour cells continues to advance and has resulted in immunotherapy medicines, such as nivolumab, that are changing the way that we treat advanced skin cancer. Nivolumab has demonstrated its potential to increase survival rates in this devastating disease, which is the ultimate goal of treatment for clinicians, patients and their families,” said Professor Jeff Evans, Director of Institute of Cancer Sciences and Professor of Translational Cancer Research at the University of Glasgow.
Nivolumab has an innovative mode of action that works by harnessing the ability of the immune system to fight advanced (metastatic or unresectable) skin cancer. It has been shown to significantly improve survival in this disease compared to chemotherapy, regardless of whether a patient has received prior treatment or not.
“Until today, we have seen an untenable situation where patients in England and Wales had access to this medicine, while those in Scotland did not,” said Gillian Nuttall, Founder, Melanoma UK. “I am delighted that today’s decision will bring new hope for patients who have been waiting for access to this medicine. I’m pleased that all parties have worked together to come to a solution for patients on this occasion, but to prevent this type of disparity continuing to affect patients in future, it is important that we work towards implementation of a more equitable medicines review process across the UK.”
The decision from the SMC is based on two pivotal Phase III trials (Checkmate -066 and -067). Data from Checkmate -066 have shown significantly more previously-untreated BRAF wild-type patients who received nivolumab were still alive at one year (72.9%), compared with those treated with the chemotherapy dacarbazine (42.1%). Furthermore, in study Checkmate -067 patients with previously untreated advanced melanoma, median progression-free survival was 6.9 months for those treated with nivolumab compared with 2.9 months in those receiving ipilimumab.
Data have also demonstrated that previously-untreated patients who received nivolumab experienced fewer serious (grade 3-4) treatment-related adverse events compared with chemotherapy (13% of patients treated with nivolumab vs. 17% of those treated with chemotherapy.
“Nivolumab is a game-changing medicine and we are delighted that NHS patients in Scotland will now have it available as a treatment option for advanced skin cancer.” said Benjamin Hickey, General Manager, UK and Ireland, BMS. “Today’s decision follows the recent SMC decision to recommend nivolumab for advanced squamous lung cancer, making the SMC the first UK reimbursement authority to recognise the value of nivolumab to patients in different cancer types. We remain committed to bringing Scottish patients rapid access to nivolumab in its additional licensed indications.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance